Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Treatment of melanoma cell lines with CCG-222740

ABSTRACT: Treatment of melanoma cell lines with CCG-222740

PROVIDER: PRJNA476556 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11954334.fastq.gz	Fastqsanger.gz
	SRR11954335.fastq.gz	Fastqsanger.gz
	SRR11954336.fastq.gz	Fastqsanger.gz
	SRR11954337.fastq.gz	Fastqsanger.gz
	SRR11954338.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

Treatment of melanoma cell lines with CCG-222740

Project description:Treatment of melanoma cell lines with CCG-222740

| PRJNA554700 | ENA

Treatment of melanoma cell lines with CCG-222740

Project description:The Ras/MEK/ERK pathway has been the primary focus of targeted therapies in melanoma, given that it is aberrantly activated in almost 80% of human cutaneous melanomas (~50% BRAFV600 mutations and ~30% NRAS mutations). While targeted therapies have yielded success in BRAFV600 mutant melanoma patients, such therapies have been ineffective in NRAS mutant melanomas in part due to their cytostatic effects and primary resistance in this patient population. Here, we demonstrate that increased Rho/MRTF-pathway activation correlates with high intrinsic resistance to trametinib, a MEK inhibitor, in a panel of NRAS mutant melanoma cell lines. Combination of trametinib with the Rho/MRTF-pathway inhibitor, CCG-222740, synergistically reduced cell viability in NRAS mutant melanoma cell lines in vitro. Furthermore, the combination of CCG-222740 with trametinib induced apoptosis and reduced clonogenicity in the highly trametinib-resistant SK-Mel-147 cells. These findings suggest a role of the Rho/MRTF-pathway in high intrinsic trametinib resistance to a subset of NRAS mutant melanoma cell lines and highlights the potential of concurrently targeting the Rho/MRTF-pathway and MEK in NRAS mutant melanomas.

2019-07-16 | GSE134320 | GEO

Treatment of melanoma cell lines with CCG-222740

2018-12-30 | GSE115938 | GEO

TGF-ß treatment of human melanoma cell lines

Project description:TGF-ß treatment of human melanoma cell lines

| PRJNA625672 | ENA

Effect of TGFb/MEKi treatment on human melanoma cell lines

Project description:Effect of TGFb/MEKi treatment on human melanoma cell lines

| PRJNA1090036 | ENA

Expression data from melanoma cell lines

2010-11-26 | GSE24862 | GEO

Enhancer connectome of melanoma cell lines

Project description:Enhancer connectome of melanoma cell lines

| PRJNA971577 | ENA

Expression data from melanoma cell lines

Project description:Differential gene expression analysis of parental and resistant sub-lines of melanoma cell lines treated or untreated with PLX4032 Using microarray we sought to obtain a genome-wide profile of differentially expressed genes in parental melanoma cell lines and resistant sub-lines in response to PLX4032 vs DMSO control treatment. Representative parental melanoma cell lines and resistant sub-lines were treated with PLX4032 at 1 uM or DMSO control for 6h. Total RNA was extracted and cDNAs were generated and hybridized onto GeneChip Human Gene 1.0 ST Arrays (Affymetrix).

2010-11-26 | E-GEOD-24862 | biostudies-arrayexpress

Cisplatin treated melanoma and melanocyte cell lines

Project description:Nucleotide excision repair (NER) orchestrates the repair of helix distorting DNA damage, induced by both ultraviolet radiation (UVR) and cisplatin. There is evidence that the global genome repair (GGR) arm of NER is dysfunctional in melanoma and it is known to have limited induction in melanoma cell lines after cisplatin treatment. The aims of this study were to examine mRNA transcript levels of regulators of GGR and to investigate the downstream effect on global transcript expression in melanoma cell lines after cisplatin treatment and in melanoma tumours.

2013-07-01 | GSE47980 | GEO

TGF-ß treatment of human melanoma cell lines

Project description:To analyse whether the activation of TGF-ß signalling (recombinant hTGF-ß, 5 ng/mL; PeproTech) is able to invoke a full phenotype- switch, we performed RNA sequencing of melanoma cultures from two independent melanoma cell lines at two different time point after TGF-β1 (5 ng/ml, preprotech).

2020-04-17 | GSE148767 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data